Ursodeoxycholic acid and cancer: from chemoprevention to chemotherapy

Goossens, Jean-Francois; Bailly, Christian

Type de document :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1016/j.pharmthera.2019.107396

PMID :

31356908

URL permanente :

http://hdl.handle.net/20.500.12210/17841

Titre :

Ursodeoxycholic acid and cancer: from chemoprevention to chemotherapy

Auteur(s) :

Goossens, Jean-Francois [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Bailly, Christian [Auteur]
Génétique moléculaire et approches thérapeutiques des hémopathies malignes

Titre de la revue :

Pharmacology & therapeutics

Nom court de la revue :

Pharmacol. Ther.

Numéro :

203

Pagination :

107396

Date de publication :

2019-07-26

ISSN :

1879-016X

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Ursodeoxycholic acid (UDCA) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid ...
Lire la suite >Ursodeoxycholic acid (UDCA) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. UDCA is also a long-established drug, largely used for the dissolution of cholesterol gallstones, the treatment of primary biliary cholangitis and other hepatobiliary disorders. The history of UDCA is briefly retraced here as well as its multifactorial mechanism of action, based on its anti-inflammatory, antioxidant and cytoprotective activities. The present review is centred around the anticancer properties of UDCA and synthetic antitumor derivatives designed over the past 20 years. Paradoxically, depending on the conditions, UDCA exhibits both pro- and anti-apoptotic properties toward different cell types. In particular, the UDCA drug can protect epithelial cells from damages and apoptosis while inducing inhibition of proliferation and apoptotic and/or autophagic death of cancer cells. The effects of UDCA on cancer cell migration, cancer stem cells and drug-induced dysbiosis are also evoked. The drug has revealed modest activities against colon and gastric cancers but may be useful to improve treatments of hepatocellular carcinoma, notably in combination with other drugs such as sorafenib. UDCA can also protect from damages induced by cancer chemotherapeutic agents. The potential of UDCA in cancer, as a chemo-protecting or chemotherapeutic agent, is highlighted here as well as the design of tumour-active derivatives, including UDCA-drug conjugates. A repurposing of UDCA in oncology should be further considered.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables

Date de dépôt :

2019-12-16T14:06:45Z
2021-06-14T08:43:59Z

Numéro de version	Lien	Date de modification
2	20.500.12210/17841*	2021-06-14T08:41:09Z
1	20.500.12210/17841.1	2019-12-16T14:06:45Z

Ursodeoxycholic acid and cancer: from ...

BibTeX

CSV

Excel

RIS

Historique des modifications

Ursodeoxycholic acid and cancer: from ... BibTeX CSV Excel RIS

Historique des modifications

Ursodeoxycholic acid and cancer: from ...

BibTeX

CSV

Excel

RIS